Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders

Title: Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders

Volume: 11 Issue: 17

Author(s): Caroline L. Smith and Patrick Vallance

Affiliation:

Keywords: nitric oxide (no), nitric oxide synthases (nos), nadph, protein arginine methyltransferases (prmt), single nucleotide polymorphisms (snp), angiogenesis, arginine, cardiovascular disorders, pre-eclampsia

Abstract: Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal failure and certain cardiovascular pathologies, and in patients with end stage renal failure the level of ADMA predicts the risk of cardiovascular events and overall mortality. The object of this review is to describe the mechanisms of ADMA synthesis, metabolism and uptake and to outline techniques for measuring ADMA and the pathological states in which ADMA levels are altered.

Cite this article as:

Smith L. Caroline and Vallance Patrick, Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders, Current Pharmaceutical Design 2005; 11 (17) . https://dx.doi.org/10.2174/1381612054367364